The quantitative determination of S-100B in serum was carried out using anenzyme linked immunosorbent assay.Results: Patients with acute ischemic stroke had significantly higher serum S-100B protein concentrations (42 pg/ml) than thoseof normal controls (31.5 pg/ml) (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aim: The aim of the present study was to evaluate serum levels of S-100B which is an acidic calcium-binding protein within thefirst 36 hours following an acute ischemic stroke and to determine the correlation between S-100B levels and National Institutes ofHealth Stroke Scale (NIHSS) scores.Material and Methods: Fifty patients with ischemic stroke (25 male, 25 female; mean age=64) and 30 healthy volunteers (14 male,16 female; mean age=61) serving as age and sex matched controls were included in this study.
📊
Key Findings & Data:Venous blood samples were takenwithin the first 36 hours following the acute stroke.
💡
Conclusion & Impact:The quantitative determination of S-100B in serum was carried out using anenzyme linked immunosorbent assay.Results: Patients with acute ischemic stroke had significantly higher serum S-100B protein concentrations (42 pg/ml) than thoseof normal controls (31.5 pg/ml) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Aim: The aim of the present study was to evaluate serum levels of S-100B which is an acidic calcium-binding protein within thefirst 36 hours following an acute ischemic stroke and to determine the correlation between S-100B levels and National Institutes ofHealth Stroke Scale (NIHSS) scores.Material and Methods: Fifty patients with ischemic stroke (25 male, 25 female; mean age=64) and 30 healthy volunteers (14 male,16 female; mean age=61) serving as age and sex matched controls were included in this study. Venous blood samples were takenwithin the first 36 hours following the acute stroke. The quantitative determination of S-100B in serum was carried out using anenzyme linked immunosorbent assay.Results: Patients with acute ischemic stroke had significantly higher serum S-100B protein concentrations (42 pg/ml) than thoseof normal controls (31.5 pg/ml) (p
🔖
Cite This Article
HAZAR, T. Y., NAZLIEL, B., İRKEÇ, C., GÜRSES, A. A., ÇAĞLAYAN, H. B. (2022). High serum S-100B protein levels within the first 36 hours of acute ischemic stroke predicts high NIHSS scores. Annals of Medical Research, Cilt: 27 - Sayı: 6, 1675–1680. https://ajindex.com/articles/446559
Bonaventura A, Liberale L, Vecchie A, et al. Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int J Mol Sci 2016;17
Rezaei O, Pakdaman H, Gharehgozli K, et al. S100 B: A new concept in neurocritical care. Iran J Neurol 2017;16:83-9
Buttner T, Weyers S, Postert T, et al. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke; J Cerebral Circulation 1997;28:1961-5
Wang S, Wang L, Zhang X, et al. Effects of subcutaneous low molecular weight heparin and intravenous unfractionated heparin on serum S100 concentrations in patients with cerebrovascular diseases. Clinical chemistry and laboratory medicine: CCLM / FESCC 2012;50:525-8
Rothermundt M, Peters M, Prehn JH, et al. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003;60:614-32
Foerch C, Otto B, Singer OC, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke; J Cerebral Circulation 2004;35:2160-4
Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke; J Cerebral Circulation 1989;20:864-70
Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke; J Cerebral Circulation 1993;24:35-41
Brea D, Sobrino T, Blanco M, et al. Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke. Clinical chemistry and laboratory medicine: CCLM / FESCC. 2009;47:1513-8
Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke; J Cerebral Circulation 2007;38:2491-5
Steiner J, Bernstein HG, Bielau H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neuroscience 2007;8:2
Dassan P, Keir G, Brown MM. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovascular Diseases 2009;27:295-302
Stroick M, Fatar M, Ragoschke-Schumm A, et al. Protein S-100B - A prognostic marker for cerebral damage.